Wednesday, December 05, 2007

Teva's COPAXONE Meets Efficacy Endpoint In PreCISe Study In Multiple Sclerosis Patients - Quick Facts [TEVA]

Teva's COPAXONE Meets Efficacy Endpoint In PreCISe Study In Multiple Sclerosis Patients - Quick Facts [TEVA]
12/3/2007 9:46:42 AM Teva Pharmaceutical Industries Ltd. (TEVA) announced the positive results from a pre-planned interim analysis of the PreCISe trial in patients presenting with a first clinical event and MRI features suggestive of multiple sclerosis or MS.
The results showed that treatment with COPAXONE (glatiramer acetate injection) reduced the risk of developing clinically definite MS (CDMS) by 44% versus placebo, and prolonged the quartile time to disease conversion to 722 days versus 336 days (+386 days, +115%) in those patients receiving placebo (hazard ratio 0.56, p=0.0005).
Teva plans to file a request for marketing authorization of COPAXONE in Europe, the U.S. and Canada for the treatment of patients with a first clinical event suggestive of MS.
The study's independent data monitoring committee recommended that the placebo arm of the trial be stopped, as COPAXONE successfully met the efficacy endpoint of the study. Data monitoring committee said that all placebo patients will now be given the opportunity to receive active treatment with COPAXONE for two years.
http://www.rttnews.com/sp/Quickfactsnew.asp?date=12/03/2007&item=95

Early Research Holds Promise For Stem Cell Therapies With Fewer ...
Medical News Today (press release) - UK
... goal of transplanting adult stem cells to create a new immune system which may help people with autoimmune conditions such as Multiple Sclerosis (MS). ...
See all stories on this topic

Medarex Announces Allowance of Investigational New Drug ...
CNNMoney.com - USA
... erythematosis and multiple sclerosis. MDX-1342 is a fully human antibody that binds selectively to CD19 expressed on B-cells (without targeting stem ...
See all stories on this topic

Hepatitis B Vaccine Is Not Linked To Multiple Sclerosis In Childhood
Medical News Today Tue, 04 Dec 2007 12:03 PM PST
Vaccinating children against the hepatitis B virus does not seem to raise that child's risk of developing Multiple Sclerosis, according to an article published in Archives of Pediatrics & Adolescent Medicine (JAMA/Archives), December 2007 issue. Numerous studies have looked at the potential link between the hepatitis B vaccine and MS (multiple sclerosis) among adults, explain the researchers. ...

Vaccination against hepatitis B does not seem to increase the risk of a first episode of MS in childhood
News-Medical-Net Tue, 04 Dec 2007 3:15 PM PST
Vaccinating against the hepatitis B virus does not appear to be associated with the risk of developing multiple sclerosis in childhood, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

Charity Succeeds In Bid To Create Quiet Time, UK
Medical News Today Tue, 04 Dec 2007 5:20 AM PST
People with multiple sclerosis (MS) across Bournemouth and the surrounding area are set to benefit from a day centre's £80,000 windfall courtesy of the Big Lottery Fund.After a disappointing defeat in a head-to-head phone vote, the Osborne Day Centre was the runner up in the People's Millions giveaway, organised in conjunction with ITV Meridian South. [click link for full article]

Early Research Holds Promise For Stem Cell Therapies With Fewer Side Effects, UK
Medical News Today Tue, 04 Dec 2007 5:19 AM PST
Early stage studies at the Stanford University School of Medicine have taken a small but significant step toward the goal of transplanting adult stem cells to create a new immune system which may help people with autoimmune conditions such as Multiple Sclerosis (MS). [click link for full article]

Targacept Says TC-2696 Intended For Acute Post-operative Pain ...
RTT News - Williamsville,NY,USA
... interim analysis of the precise trial in patients presenting with a first clinical event and MRI features suggestive of multiple sclerosis or MS. ...
See all stories on this topic

The Impact and Burden of Multiple Sclerosis
Medscape (subscription) - USA
The national and regional prevalence of multiple sclerosis (MS) in France was reported at the 2007 European Committee for Treatment and Research in Multiple ...
See all stories on this topic

Hepatitis B Vaccine Is Not Linked To Multiple Sclerosis In Childhood
Vaccinating children against the hepatitis B virus does not seem to raise that child's risk of developing Multiple Sclerosis, according to an article published in Archives of Pediatrics & Adolescent Medicine (JAMA/Archives), December 2007 issue.

Charity Succeeds In Bid To Create Quiet Time, UK
People with multiple sclerosis (MS) across Bournemouth and the surrounding area are set to benefit from a day centre's £80,000 windfall courtesy of the Big Lottery Fund.After a disappointing defeat in a head-to-head phone vote, the Osborne Day Centre was the runner up in the People's Millions giveaway, organised in conjunction with ITV Meridian South.

Early Research Holds Promise For Stem Cell Therapies With Fewer Side Effects, UK
Early stage studies at the Stanford University School of Medicine have taken a small but significant step toward the goal of transplanting adult stem cells to create a new immune system which may help people with autoimmune conditions such as Multiple Sclerosis (MS).

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home